Use of angiotensin system inhibitors is associated with significant survival benefits in metastatic renal cell carcinoma patients treated in the targeted therapy era, research findings indicate.

Follow this link:
Angiotensin system inhibitor use improves metastatic RCC survival outcomes

Leave a Reply